{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:24:26Z","timestamp":1769639066954,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.jaad.2011.10.009","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T08:16:07Z","timestamp":1321517767000},"page":"400-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis"],"prefix":"10.1016","volume":"67","author":[{"given":"Benjamin C.","family":"Garden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jaad.2011.10.009_bib1","first-page":"S19","article-title":"Epidermal growth factor receptor as a target for chemotherapy","volume":"5","author":"Vallbohmer","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-4632.2010.04791.x","article-title":"Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors","volume":"50","author":"Balagula","year":"2011","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib3","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1002\/cncr.25090","article-title":"Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life","volume":"116","author":"Joshi","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib5","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1097\/JTO.0b013e3181e981d9","article-title":"Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer","volume":"5","author":"Becker","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib6","first-page":"1079","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients","volume":"55","author":"Ro\u00e9","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib9","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10549-008-0020-7","article-title":"Analysis of dermatologic events in patients with cancer treated with lapatinib","volume":"114","author":"Lacouture","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaad.2011.10.009_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: panitumumab (Vectibix)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jaad.2011.10.009_bib11","unstructured":"Erbitux package insert: Available at: http:\/\/www.erbitux.com\/."},{"key":"10.1016\/j.jaad.2011.10.009_bib12","unstructured":"Vectibix package insert: Available at: http:\/\/www.vectibix.com\/."},{"key":"10.1016\/j.jaad.2011.10.009_bib13","unstructured":"Tarceva package insert: Available at: http:\/\/www.tarceva.com\/."},{"key":"10.1016\/j.jaad.2011.10.009_bib14","unstructured":"Lapatinib package insert: Available at: http:\/\/www.fda.gov."},{"key":"10.1016\/j.jaad.2011.10.009_bib15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/JTO.0b013e3181943bb9","article-title":"A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small-cell lung cancer","volume":"4","author":"Akerley","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/annonc\/mdq604","article-title":"A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma","volume":"22","author":"Chan","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib17","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1158\/1078-0432.CCR-06-0260","article-title":"Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study","volume":"12","author":"Giaccone","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2011.10.009_bib18","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1200\/JCO.2006.08.2263","article-title":"Phase II trial of cetuximab in patients with previously treated non-small cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/cncr.22915","article-title":"Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer","volume":"110","author":"Hecht","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib20","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2006.07.5754","article-title":"Phase II clinical trial of chemotherapy-naive patients \u226570 years of age treated with erlotinib for advanced non-small cell lung cancer","volume":"25","author":"Jackman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib21","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/JTO.0b013e31818d6702","article-title":"Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study","volume":"3","author":"Kubota","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-010-1280-6","article-title":"Phase II study of erlotinib for chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets","volume":"67","author":"Lee","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaad.2011.10.009_bib23","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.oraloncology.2008.07.010","article-title":"Cetuximab in recurrent and\/or metastatic salivary gland carcinomas: A phase II study","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jjco\/hyp016","article-title":"A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer","volume":"39","author":"Muro","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib26","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2007.15.8808","article-title":"Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148","volume":"26","author":"Oza","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/annonc\/mdm516","article-title":"First-line single-agent cetuximab in patients with advanced colorectal cancer","volume":"19","author":"Pessino","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib28","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1200\/JCO.2010.33.4094","article-title":"Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)","volume":"29","author":"Ramalingam","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.22886","article-title":"Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma","volume":"110","author":"Thomas","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/JTO.0b013e3181b270a7","article-title":"Erlotinib monotherapy for stage IIIB\/IV non-small cell lung cancer: a multicenter trial by the Korean Cancer Study Group","volume":"4","author":"Uhm","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib32","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/annonc\/mdm399","article-title":"An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy","volume":"19","author":"Van Cutsem","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib33","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib34","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","volume":"25","author":"Vermorken","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib35","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.7078","article-title":"A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation","volume":"28","author":"Neal","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib36","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8510","article-title":"Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study","volume":"28","author":"Maubec","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1078155208100450","article-title":"Nail toxicity induced by cancer chemotherapy","volume":"15","author":"Gilbar","year":"2009","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jaad.2011.10.009_bib38","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients, case 1: paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/00002018-199921030-00004","article-title":"Drug-induced nail disorders: incidence, management and prognosis","volume":"21","author":"Piraccini","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.jaad.2011.10.009_bib40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2006.09.005","article-title":"Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management","volume":"56","author":"Hu","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1468-3083.2009.03516.x","article-title":"Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia","volume":"24","author":"Eames","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2011.10.009_bib43","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1111\/j.1365-2230.2008.03162.x","article-title":"Magnetic resonance imaging of paronychia induced by cetuximab","volume":"34","author":"Konheim","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib44","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula","year":"2010","journal-title":"J Support Oncol"},{"issue":"5 Suppl. 2","key":"10.1016\/j.jaad.2011.10.009_bib45","first-page":"26","article-title":"Pathology and management of dermatologic toxicities associated with anti-EGFR therapy","volume":"20","author":"Fox","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaad.2011.10.009_bib46","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2011.10.009_bib47","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib48","first-page":"309","article-title":"Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials","volume":"7","author":"Bauer","year":"2008","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","article-title":"Nail toxicity associated with epidermal growth factor receptor inhibitor therapy","volume":"56","author":"Fox","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib50","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2011.10.009_bib51","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2230.2008.02928.x","article-title":"Acute paronychia caused by lapatinib therapy","volume":"34","author":"Rigopoulos","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2011.10.009_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/2229-5178.73251","article-title":"Lapatinib-induced acute generalized exanthematous pustulosis","volume":"1","author":"Lakshmi","year":"2010","journal-title":"Indian Dermatol Online J"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211011339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962211011339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:23:06Z","timestamp":1759270986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962211011339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0190962211011339"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2011.10.009","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2011.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}